Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells

BACKGROUND: Mesenchymal stem/stromal cells (MSC) accumulate and reside in tumor sites. METHODS: Taking advantage of this feature in anticancer therapy, immortalized murine MSC (iMSC) were genetically altered to produce chemokine (C-C motif) ligand 19 (iMSC/CCL19), which attracts dendritic cells (DC)...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Iida, Yuichi, Yoshikawa, Rintaro, Murata, Akihiko, Kotani, Hitoshi, Kazuki, Yasuhiro, Oshimura, Mitsuo, Matsuzaki, Yumi, Harada, Mamoru
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Immune Cell Therapies and Immune Cell Engineering
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7368496/
https://ncbi.nlm.nih.gov/pubmed/32675195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000582
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller